Xeris Pharmaceuticals company info

What does Xeris Pharmaceuticals do?
Xeris Pharmaceuticals (NASDAQ:XERS) is engaged in developing and commercializing innovative therapies in endocrinology and neurology. The company focuses on creating products that use its proprietary formulation technology platforms, including XeriSol™ and XeriJect™, which are designed to enhance the efficacy, safety, and convenience of therapies for patients with serious and chronic medical conditions. Xeris Pharmaceuticals aims to address significant unmet medical needs by bringing to market treatments that offer better clinical outcomes and more accessible patient care. Its portfolio includes Gvoke® for severe hypoglycemia in diabetes patients, reflecting the company's commitment to improving the lives of those living with challenging medical conditions. Through ongoing research and development, Xeris seeks to expand its product offerings and deliver innovative healthcare solutions worldwide.
Xeris Pharmaceuticals company media
Company Snapshot

Is Xeris Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Xeris Pharmaceuticals employ?

people
Employees
377

What sector is Xeris Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Xeris Pharmaceuticals?

location pin
Head Office
Chicago, United States

What year was Xeris Pharmaceuticals founded?

founded flag
Year Founded
2005
What does Xeris Pharmaceuticals specialise in?
/Glucagon Products /Hypoglycemia Treatment /XeriSol Technology /XeriJect Technology /Medication Delivery /Innovative Research

What are the products and/or services of Xeris Pharmaceuticals?

Overview of Xeris Pharmaceuticals offerings
Gvoke HypoPen and PFS, a ready-to-use, room-temperature stable liquid glucagon for severe hypoglycemia.
Recorlev (levoketoconazole), a cortisol synthesis inhibitor for endogenous Cushing’s syndrome treatment.
Keveyis (dichlorphenamide), the first FDA-approved drug for primary hyperkalemic and hypokalemic periodic paralysis.
XeriJect technology, focusing on formulation technology for injectable and infusible drug candidates.
Self-administered glucagon for exercise-induced hypoglycemia, offering a convenient option for individuals with diabetes.
A pipeline of developmental programs targeting endocrine disorders, leveraging novel delivery technologies for better patient care.

Who is in the executive team of Xeris Pharmaceuticals?

Xeris Pharmaceuticals leadership team
  • Mr. Paul R. Edick
    Mr. Paul R. Edick
    Chairman & CEO
  • Mr. John P. Shannon
    Mr. John P. Shannon
    President & COO
  • Ms. Beth P. Hecht J.D.
    Ms. Beth P. Hecht J.D.
    Chief Legal Officer & Corporate Secretary
  • Mr. Steven M. Pieper
    Mr. Steven M. Pieper
    Chief Financial Officer
  • Ms. Allison  Wey
    Ms. Allison Wey
    Senior Vice President of Investor Relations & Corporate Communications
  • Dr. Kenneth E. Johnson Pharm. D., Pharm.D.
    Dr. Kenneth E. Johnson Pharm. D., Pharm.D.
    Senior VP of Global Development & Medical Affairs
  • Mr. Kevin  McCulloch
    Mr. Kevin McCulloch
    Chief Commercial Officer